Evidence map›Paper›PMID 35335101›Full record

ReviewVaccines2022

Effectiveness of BNT162b2 and mRNA-1273 Vaccines against COVID-19 Infection: A Meta-Analysis of Test-Negative Design Studies.

Shuailei Chang, Hongbo Liu, Jian Wu, Wenwei Xiao, Sijia Chen, Shaofu Qiu, Guangcai Duan, Hongbin Song, Rongguang Zhang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Effectiveness of first, second, and third COVID-19 vaccine doses in solid organ transplant recipients: A population-based cohort study from Canada.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2022
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shuailei ChangDepartment of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou 450001, China.
Hongbo LiuChinese PLA Center for Disease Control and Prevention, Beijing 100071, China.
Jian WuDepartment of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou 450001, China.
Wenwei XiaoDepartment of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou 450001, China.
Sijia ChenDepartment of Epidemiology, College of Public Health, China Medical University, Shenyang 110122, China.
Shaofu QiuChinese PLA Center for Disease Control and Prevention, Beijing 100071, China.
Guangcai DuanDepartment of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou 450001, China.
Hongbin SongChinese PLA Center for Disease Control and Prevention, Beijing 100071, China.
Rongguang ZhangDepartment of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou 450001, China.ORCID 0000-0001-9961-2434

Funding

National key research and development program 2017YFC1600105National key research and development program 2019YFC1200702the National Nature Science Foundation of China 81673237the National Nature Science Foundation of China 81873968
6 · The paper itself

Abstract

Although numerous COVID-19 vaccines are effective against COVID-19 infection and variants of concern (VOC) in the real world, it is imperative to obtain evidence of the corresponding vaccine effectiveness (VE). This study estimates the real-world effectiveness of the BNT162b2 and mRNA-1273 vaccines against COVID-19 infection and determines the influence of different virus variants on VE by using test-negative design (TND) studies. We systematically searched for published articles on the efficacy of BNT162b2 and mRNA-1273 against COVID-19 infection. Two researchers independently selected and extracted data from eligible studies. We calculated the VE associated with different vaccine types, SARS-CoV-2 variants, and vaccination statuses, using an inverse variance random-effects model. We selected 19 eligible studies in the meta-analysis from 1651 records. For the partially vaccinated group, the VE of BNT162b2 and mRNA-1273 was 61% and 78% against COVID-19 infection, respectively. For the completely vaccinated group, the VE of BNT162b2 and mRNA-1273 was 90% and 92% against COVID-19 infection, respectively. During subgroup analyses, the overall VE of BNT162b2 and mRNA-1273 against the Delta variant was 53% and 71%, respectively, for the partially vaccinated group; the respective VE values were 85% and 91% for the fully vaccinated group. Irrespective of the BNT162b2 or mRNA-1273 vaccines, the Delta variant significantly weakened vaccine protection for the partially vaccinated group, while full vaccination was highly effective against COVID-19 infection and various VOC. The mRNA-1273 vaccine is more effective against COVID-19 infection and VOC than the BNT162b2 vaccine, especially for the partially vaccinated group. Overall, the results provide recommendations for national and regional vaccine policies.

Indexed as

BNT162b2 vaccineCOVID-19 infectionmeta-analysismRNA-1273 vaccinetest-negative designvaccine effectiveness

Identifiers

PMID35335101
PMCPMC8954872

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.